NYU Abu Dhabi Researchers Develop Innovative Tool To Enhance Cold-Temperature Cancer Surgery Precision

Researchers at NYU Abu Dhabi (NYUAD) have created a tool that aids surgeons in identifying and removing cancer cells during cryosurgery. This procedure uses extreme cold to eliminate tumours. The new technology employs a nanoscale material that lights up cancer cells when frozen, helping distinguish them from healthy tissue and enhancing surgical accuracy.

The Trabolsi research group at NYUAD developed a unique nanoscale Covalent Organic Framework (nTG-DFP-COF). This material increases its fluorescence under extreme cold, allowing clear differentiation between cancerous and healthy tissues during surgery. Their study, "Freezing-Activated Covalent Organic Frameworks for Precise Fluorescence Cryo-Imaging of Cancer Tissue," was published in the Journal of the American Chemical Society.

This advancement not only boosts the precision and safety of cryosurgical procedures but also merges diagnostic and treatment functions into one platform. It helps surgeons preserve more healthy tissue while removing cancer cells. This integration could reduce the need for repeat surgeries and speed up patient recovery.

"We believe this is a transformative tool that could revolutionise cancer surgery," said Farah Benyettou, Ph.D., a research scientist in the Trabolsi Research Group at NYU Abu Dhabi. "By making tumor removal more precise, this technology has the potential to reduce additional surgeries and accelerate patient recovery. It’s a major step forward in treating aggressive, hard-to-target cancers."

Ali Trabolsi, Professor of Chemistry and principal investigator of the Trabolsi Research Group at NYU Abu Dhabi, stated, "This breakthrough bridges the gap between imaging and therapy, providing surgeons with a real-time tool to visualise and remove cancer with unprecedented precision." By integrating fluorescence imaging with cryosurgery, they are advancing cancer treatment options.

This innovation offers new hope for patients with challenging-to-treat tumours by pushing the boundaries of current cancer treatments. The combination of imaging and therapy in one platform represents a significant leap forward in medical technology.

The development of this tool signifies progress in treating aggressive cancers that are difficult to target. By improving surgical outcomes and reducing recovery times, it holds promise for enhancing patient care significantly.

With inputs from WAM